Research: CARRARO and colleagues, P

Listed in Issue 19


CARRARO and colleagues, Perre Fabre Medicament, La Chartreuse, Castres, France, noting the controversy regarding the relative efficacy of treatments for the relief of symptoms of benign prostatic hyperplasia (BPH), compared the use of 320 mg plant extract Permixon with 5 mg finasteride, a 5-alpha-reductase inhibitor, in the treatment of BPH. @m: The authors conducted a 6-month double-blind randomised study with more than 1000 men with moderate BPH, using the criteria of the International Prostate Symptom Score (IPSS) as the primary end-point. @r: Both Permixon and finasteride decreased the IPSS (-37% and -39%) , improved the quality of life (38% and 41%) and increased peak urinary flow rate (+25% and +30%). Finasteride markedly decreased prostate volume (-18%) and serum PSA levels (-41%). Permixon improved symptoms with little effect upon volume (-6%) and no change in PSA levels. Permixon was superior to finasteride in a sexual function questionnaire and give rise to fewer complaints of decreased libido and impotence. @c: Both treatments relieve BPH treatments in two-thirds of patients. Permixon, unlike finasteride, has little effect upon so-called androgen-dependent parameters, suggesting that other pathways may also be involved in BPH symptomatology. @q:Carraro JC et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29(4): 231-40. Oct 1996.






ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page